FRANKFURT (Reuters) – Roche’s CEO said on Wednesday that the Swiss drugmaker’s oral drug candidate for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($11.66 billion) annually if it succeeds in two key trials on early treatment of the disease.
“Giredestrant, if it works, would be a product in a market with a potential of 1 billion-plus,” CEO Thomas Schinecker said at a media event in Mannheim, Germany.
($1 = 0.8576 Swiss francs)
(Reporting by Ludwig Burger; Editing by Madeline Chambers)
